|drug3291||Recombinant human angiotensin-converting enzyme 2 (rhACE2) Wiki||1.00|
There is one clinical trial.
The vast majority of individuals with Covid19 have mild illness that can be managed in the outpatient setting. A small but significant number of these people will deteriorate and require hospitalization. Symptoms are a poor - and possibly late - indicator for deterioration. While people who have died, and/or been cared for in the ICU or hospital have been well characterized, there remains a dearth of information about the clinical course of people in the outpatient setting. Most notably, it is not known when to escalate to hospital care. The consequence of non-escalation when needed is significant patient morbidity and mortality, of escalation when not needed is unnecessarily overwhelmed hospitals. Technologies for clinical management and early diagnostics for severe Covid19 infection will address this challenge. The research goal of this study is to use real-time remote patient monitoring to detect which patients with Covid19 are at risk of deterioration to bring to hospital, while at the same ensuring the worried will receive reassurance so they stay at home. The clinical goal is to help clinicians provide excellent care using ubiquitous mobile phones.
Description: Number of participants with an unplanned emergency department visits leading to hospital admissionMeasure: Number of participants with an unplanned hospital admissions Time: 30 days
Description: Number of participants with planned hospital admissions that are found to be necessaryMeasure: Number of participants with planned hospital admissions that are found to be necessary Time: 30 days
Description: Number of participants with an emergency department visit not resulting in a hospital admissionMeasure: Number of participants with an emergency department visits not resulting in hospital admission Time: 30 days
Description: Number of planned hospital admissions which are found to be unnecessaryMeasure: Number of planned hospital admissions which are found to be unnecessary Time: 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports